Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?

Saha S, Chant D, McGrath J.

Arch Gen Psychiatry. 2007 Oct;64(10):1123-31. Review.

PMID:
17909124
2.

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators..

N Engl J Med. 2007 Sep 27;357(13):1301-10.

3.

Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.

Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE.

Neuropsychopharmacology. 2008 Apr;33(5):985-94.

4.

Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study.

Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N.

BMC Psychiatry. 2007 Apr 23;7:14.

6.

Diagnosis and classification of diabetes mellitus.

American Diabetes Association..

Diabetes Care. 2007 Jan;30 Suppl 1:S42-7. No abstract available.

PMID:
17192378
8.

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group..

Schizophr Res. 2007 Feb;90(1-3):162-73.

PMID:
17123783
9.

Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.

Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H.

Neuropsychopharmacology. 2007 Feb;32(2):289-97.

10.

Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.

Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, Evins AE, Zhang H, Hayden DL, Freudenreich O, Cather C, Schoenfeld DA, Goff DC.

J Clin Psychiatry. 2006 May;67(5):789-97.

PMID:
16841629
11.

Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary.

American Heart Association.; National Heart, Lung, and Blood Institue., Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F.

Cardiol Rev. 2005 Nov-Dec;13(6):322-7. No abstract available.

PMID:
16708441
12.

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.

Alberti KG, Zimmet P, Shaw J.

Diabet Med. 2006 May;23(5):469-80. Review.

PMID:
16681555
13.

Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication.

De Hert MA, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J.

Schizophr Res. 2006 Mar;83(1):87-93.

PMID:
16481149
14.

High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia.

Hägg S, Lindblom Y, Mjörndal T, Adolfsson R.

Int Clin Psychopharmacol. 2006 Mar;21(2):93-8.

PMID:
16421460
15.

Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus.

Wannamethee SG, Shaper AG, Lennon L, Morris RW.

Arch Intern Med. 2005 Dec 12-26;165(22):2644-50.

PMID:
16344423
16.

Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes.

Guzder RN, Gatling W, Mullee MA, Byrne CD.

Diabetologia. 2006 Jan;49(1):49-55.

PMID:
16341841
17.

A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls.

Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D'Agostino RB, Stroup TS, Davis S, Lieberman JA.

Schizophr Res. 2005 Dec 1;80(1):45-53.

PMID:
16198088
18.

Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.

Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Evins AE, Cather C, Goff DC.

J Clin Psychiatry. 2005 Sep;66(9):1116-21.

PMID:
16187768
19.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators..

N Engl J Med. 2005 Sep 22;353(12):1209-23. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3.

20.

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA.

Schizophr Res. 2005 Dec 1;80(1):19-32.

PMID:
16137860
Items per page

Supplemental Content

Support Center